Skip to main content
SpringerLink
Log in

Kardiales, renales und vaskuläres Protektionspotential der ACE-Hemmer

  • Conference paper
Blutdrucksenkung heute — Korrektur von Struktur und Funktion der Arterie

  • 20 Accesses

Zusammenfassung

Das Wirkprofil der ACE-Hemmer weist entsprechend den Wirkungen von Angiotensin II ein weites Spektrum auf.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Pfeffer JM, Pfeffer MA, Braunwald E (1985) Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circul Res 57: 84–95

    Article  CAS  Google Scholar 

  2. Pfeffer MA, Lamas GA, Vaughu DE, Parisi AE, Braunwald E (1988) Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 319: 80–86

    Article  PubMed  CAS  Google Scholar 

  3. Portaluppi F, Padula A, Alfiero R, Rizzo A (1985) Ergometric evaluation of the effects of captopril in hypertensive patients with stable angina. J Hypertension 3 (Suppl II): 147 —148

    Google Scholar 

  4. The Consensus Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 316: 1429–1435

    Article  Google Scholar 

  5. Webster MWI, Fitzpatrick MA, Nickolls G, Ikram H, Wells JE (1985) Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 56: 566–569

    Article  PubMed  CAS  Google Scholar 

  6. Asmar RG, Journo HJ, Lacolley PJ, Levy BI, Safar ME (1988) Treatment for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension. J Hypertension 6 (Suppl 3): S 33—S 39

    Google Scholar 

  7. Klaus D (1985) Regression der Linksherzhypertrophie beim arteriellen Blutdruck: Grundlagen, experimentelle und klinische Befunde. Z Kardiol 75 (Suppl 7): 153–169

    Google Scholar 

  8. Kannel WB, Gordon T, Castelli WP, Margolis JR (1970) ECG-left ventricular hypertrophy and risk of CHD. The Framingham Study. Am Int Med 72: 813

    Google Scholar 

  9. Santoni JP, Asmar RG, Bizot-Espiarch JG, Safar M (1989) Enregistrement ambulatoire de la pression artérielle lors d’un traitement par le perindopril. Arch Mal Cceur 82/1:51 — 56

    Google Scholar 

  10. Diamond JR, Karnovsky MJ (1988) Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 33: 917–924

    Article  PubMed  CAS  Google Scholar 

  11. Anderson S, Meyer TW, Rennke HG, Brenner BM (1985) Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76: 612–619

    Article  PubMed  CAS  Google Scholar 

  12. Kardiales, renales und vaskuläres Protektionspotential der ACE-Hemmer Taguma Y, Kitamoto Y, Futaki G, Ueda H, Takahashi H, Sasaki Y (1985) Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 313: 1617–1620

    Google Scholar 

  13. Parving H-H, Hommel E, Schmidt UM (1988) Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. Br Med J 297: 1086–1091

    Article  CAS  Google Scholar 

  14. Mimram A, Insua A, Ribstein J, Monnier L, Bringer J, Mirouze J (1988) Contrasting effects of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. J Hypertension 6: 619–923

    Article  Google Scholar 

  15. Textor SC, Gephardt GN, Bravo EW, Tarazi RC, Fouad FM, McMahon JT (1983) Membranous glomerulopathy associated with captopril therapy. Am J Med 74: 705–712

    Article  PubMed  CAS  Google Scholar 

  16. Parving H-M, Anderson AR, Smidt UM, Svendsen PA (1983) Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet I: 1175–1179

    Google Scholar 

  17. Reisch C, Mann J, Ritz E (1987) Konversionsenzymhemmer in der antihypertensiven Behandlung niereninsuffizienter Patienten. Dtsch Med Wochenschr 112: 1249–1252

    Article  PubMed  CAS  Google Scholar 

  18. Klaus D (1988) Der Stellenwert von Konversionsenzymhemmern in der Hypertoniebehandlung. Z Kardiol 77 (Suppl 3): 73–88

    PubMed  Google Scholar 

  19. Berk BC, Vekshtein V, Gordon MH, Tsuda T (1989) Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 13: 305–314

    Article  PubMed  CAS  Google Scholar 

  20. Levy BI, Michel J-B, Salzmann JL, Camilleri JP, Safar ME (1988) Arterial effects of angiotensin converting enzyme inhibition in renovascular and spontaneously hypertensive rats. J Hypertension 6 (Suppl 3): S 23 —S 25

    Google Scholar 

  21. Christensen HRL, Nielsen H, Christensen KL, Jespersen LT, Mulvany MJ (1988) Longterm hypotensive effects of an angiotensin converting enzyme inhibitor in spontaneously hypertensive rats: is there a role for vascular structure? J Hypertension 1988 6 (Suppl 3): S27 — S31

    CAS  Google Scholar 

  22. Heagerty AM, Bund SJ, Alkjaer C (1988) Effects of drug treatment on human resistance arteriole morphology: direct evidence for structural remodelling of resistance vessels. Lancet II: 1209–1212

    Google Scholar 

  23. Santoni J-P, Asmar R, Safar ME (1989) Angiotensin converting enzyme inhibition, pulse wave velocity and ambulatory blood pressure measurements in essential hypertension. Clin Exp (Theory and Practice) All (Suppl 2 ): 535–544

    Google Scholar 

  24. Hostetter TM, Renke MG, Brenner GM (1982) The case for intrarenal hypertension in the initation and progression of diabetic and other glomerulopathies. Am J Med 72: 375380

    Google Scholar 

  25. Speirs CJ, Mollery CT, Inman WHW, Rawson NSB, Wilton LV (1988) Postmarketing surveillance of enalapril, II: Investigation of the potential role of enalapril in deaths with renal failure. Br Med J 297: 830–832

    Google Scholar 

  26. Cleland JGF, Dargie HJ, Ball SG, Gillen G, Ford I, Robertson JIS (1985) Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones and metabolic state. Br Heart J 54: 305–312

    Article  PubMed  CAS  Google Scholar 

  27. Kramer BL, Massie BM, Topic N (1983) Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation 67: 807–816

    Article  PubMed  CAS  Google Scholar 

  28. Dzau VJ (1989) Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities, and hypotheses. J Hypertension 7: 933–936

    Article  CAS  Google Scholar 

  29. Safar ME (1989) Pulse pressure in essential hypertension: clinical and therapeutical implications. J Hypertension 7: 769–776

    Article  CAS  Google Scholar 

  30. Marre M, Chatellier G, Leblanc H, Menard J, Pussa P (1988) Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J 297: 1092–1095

    Article  CAS  Google Scholar 

  31. Chobanian AV, Haudenschild CC, Nickerson C, Drago R (1990) Antiatherogenic effect of captopril in the Watanale heritable hyperlipidemic rat. Hypertension 15: 327–331

    Article  PubMed  CAS  Google Scholar 

  32. Parving M-H, Hommel E, Nielsen MD, Giese J (1989) Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. Br Med J 289: 533–536

    Article  Google Scholar 

  33. D. Klaus: Kardiales, renales und vaskuläres Protektionspotential der ACE-Hemmer Schölkens BA, Becker RMA, Linz W (1988) Pharmakologische Beeinflussung des Konversionsenzyms — lokale und systemische Effekte an Herz und GeraBen. Z Kardiol 77 (Suppl 3 ): 13–21

    Google Scholar 

  34. Schilling H, Scheler F (1988) ACE-Hemmung, Nebenwirkungen und Risiken. Z Kardiol 77 (Suppl 3): 47–54

    PubMed  Google Scholar 

  35. Björk S, Mulec H, Johnson SH, Nyberg G, Aurell M (1990) Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. Br Med J 300: 904–907

    Article  Google Scholar 

Download references

Authors
  1. D. Klaus
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinische Poliklinik, Universität Bonn, Wilhelmstr. 35-37, W-5300, Bonn 1, Bundesrepublik Deutschland

    Klaus O. Stumpe

  2. Medizinische Klinik, Städtische Kliniken Dortmund, Beurhausstr. 40, W-4600, Dortmund 1, Bundesrepublik Deutschland

    Dieter Klaus

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Klaus, D. (1990). Kardiales, renales und vaskuläres Protektionspotential der ACE-Hemmer. In: Stumpe, K.O., Klaus, D. (eds) Blutdrucksenkung heute — Korrektur von Struktur und Funktion der Arterie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-85813-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85813-0_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-53417-4

  • Online ISBN: 978-3-642-85813-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation